Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14).
Nizar J BahlisRachid BazSimon J HarrisonHang QuachShir Jing HoAnnette Juul VangstedTorben PlesnerPhillipe MoreauSimon D GibbsSheryl CoppolaXiaoqing YangAbdullah Al MasudJeremy A RossOrlando BuenoJonathan L KaufmanPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
VenDd and VenDVd produced a high rate of deep and durable responses in patients with RRMM. These results support continued evaluation of venetoclax with daratumumab regimens to treat RRMM, particularly in those with t(11;14).